NCT01721837已完成不适用
Use of Pradaxa® (Dabigatran Etexilate) for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Mild to Moderate Renal Impairment
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 4,340
- 试验地点
- 1,616
- 主要终点
- Creatinine Clearance (Recalculated Using Entries of Age, Gender, Body Weight and Serum Creatinine Made by the Physician)
研究概览
简要总结
Non-interventional, observational study of physicians' use of Dabigatran etexilate for stroke prevention in patients with atrial fibrillation and mild to moderate renal impairment
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Creatinine Clearance (Recalculated Using Entries of Age, Gender, Body Weight and Serum Creatinine Made by the Physician)
时间窗: One single observation time point: at the time of prescription before the first intake of dabigatran etexilate
The creatinine clearance was recalculated with the Cockcroft-Gault formula using age, gender, body weight, and serum creatinine.
次要结局
未报告次要终点
研究者
研究点 (1616)
Loading locations...
相似试验
已完成
4 期
Use of Dabigatran Etexilate to Prevent Stroke and ThromboembolismAtrial FibrillationAtrial FlutterNCT01976507Vanderbilt University Medical Center101
已完成
4 期
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran EtexilateArthroplasty, ReplacementPrevention of Venous ThromboembolismModerate Renal Impairment (CrCl 30-50 mL/Min)NCT01184989Boehringer Ingelheim142
已完成
2 期
Dabigatran Treatment Following Transient Ischemic Attack and Minor StrokeMinor Ischemic StrokeTransient Ischemic AttackNCT01769703University of Alberta53
已完成
不适用
Andexanet Alfa: Non-interventional Study in Stroke Units in Germany (DE)Intracranial HemorrhagesNCT05127941University Hospital, Essen141
已完成
1 期
Investigation Drug-drug Interaction Between Dabigatran and ClarithromycinHealthyNCT01385683Centre Hospitalier Universitaire de Saint Etienne10